3 tracked public figures made calls on RLAY. We grade SELL/REDUCE calls as Correct/Incorrect/Pending, and compare BUY/ADD returns against the S&P 500 over matched windows.
On average, public BUY calls on Relay Therapeutics beat the S&P 500 by +33.7%.
| Who | Signal | Date | Return / Grade | Buy vs S&P | Source |
|---|---|---|---|---|---|
| Scott Minerd | BUY | Sep 07, 2025 | +144.1% | -0.0% | source ↗ |
| Savita Subramanian | BUY | Mar 12, 2026 | -6.1% | -2.6% | source ↗ |
| Charlie Scharf | BUY | Mar 12, 2026 | -6.1% | -2.6% | source ↗ |
| Scott Minerd | BUY | Mar 13, 2026 | -4.3% | -2.1% | source ↗ |
Scott Minerd currently ranks #1 on RLAY with +69.9% average buy return vs -1.1% for the S&P 500 (+70.9% alpha) across 2 scored buy calls.
Yes. Across 4 scored BUY/ADD calls, average return is +31.9% vs -1.8% for the S&P 500 (+33.7% alpha).
SELL/REDUCE calls are shown as Correct, Incorrect, or Pending. Only BUY/ADD calls are compared directly against the S&P 500 in the ticker-level return stats.